

# Impact of pharmaceutical intervention in women with epilepsy

<b>Submission date</b> 27/04/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 07/06/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 21/02/2022	<b>Condition category</b> Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Martha Losada-Camacho

**Contact details**  
Crr 30 45-03 Edificio 450  
Farmacia Oficina 215  
Ciudad Universitaria  
Bogotá  
Colombia  
001  
+57 (0)1 3114445288  
mlosadac@unal.edu.co

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
01-2010



# Study information

## Scientific Title

Impact of pharmaceutical intervention in the treatment and quality of life of women with epilepsy: a randomised controlled pragmatic clinical trial

## Acronym

IPHIWWE

## Study objectives

Will the intervention of the pharmacist in the therapy of women with epilepsy to optimise treatment and improve their quality of life?

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Local medical ethics committee (Fundación Liga Central Contra la Epilepsia, sede Bogotá, LICCE, Acta 18/2009 Comité de Ética), 11/08/2009, ref: CEI-A1. Acta 18 de 2009

## Study design

Randomised controlled pragmatic trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Other

## Study type(s)

Quality of life

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Epilepsy

## Interventions

This is a two-armed pragmatic trial. The intervention group will receive usual medical care and are additionally given pharmaceutical care, health education and therapeutic drugs monitoring for six months. The control group continued with standard medical care.

All the patients continued drug treatment prescribed by the physician. Questionnaire measures will be administered to all participants at the beginning of baseline recording and at the end of the study.



**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome measure**

Quality of Life in Epilepsy Inventory-31 (QOLIE-31). Questionnaire measures will be administered to all participants at the beginning of baseline recording and at the end of treatment (six months).

**Secondary outcome measures**

Questionnaire measures will be administered to all participants at the beginning of baseline recording and at the end of treatment (six months):

1. Liverpool Adverse Events Profile
2. Spanish Center for Epidemiologic Studies, Depression Scale
3. Drug related problems

**Overall study start date**

03/05/2010

**Completion date**

28/02/2011

**Eligibility****Key inclusion criteria**

1. Female, over 18 years
2. Diagnosis of epilepsy for more than a year
3. In treatment with antiepileptic drugs
4. Having at least one crisis in the last year
5. Ability to comply with the directions of the study

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Female

**Target number of participants**

182 patients

**Total final enrolment**

182



**Key exclusion criteria**

1. Active major psychiatric disorder
2. Physical deficit (e.g., hemiplegia) or mental (e.g., mental retardation), preventing them from answering questionnaires
3. Drug/alcohol dependence
4. Involvement, earlier in the pharmaceutical care program of the institution

**Date of first enrolment**

03/05/2010

**Date of final enrolment**

28/02/2011

**Locations****Countries of recruitment**

Colombia

**Study participating centre**

Crr 30 45-03 Edificio 450

Bogotá

Colombia

001

**Sponsor information****Organisation**

Universidad Nacional de Colombia (Colombia)

**Sponsor details**

Dirección de Investigación Sede Bogotá

Cra. 45 26-85 (Edificio "Uriel Gutiérrez") Of. 206 y 219

Bogotá

Colombia

001

**Sponsor type**

University/education

**Website**

<http://www.unal.edu.co/>

**ROR**

<https://ror.org/059yx9a68>



# Funder(s)

## Funder type

University/education

## Funder Name

Universidad Nacional de Colombia (Colombia) - Research Division of Bogotá (DIB) (ref: 202010011419 Quipu Code)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

Not provided at time of registration

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	31/10/2014		Yes	No
<a href="#">Results article</a>		15/02/2022	21/02/2022	Yes	No